Smart Mandibular Advancement Device (MAD) for sleep monitoring

阻塞性睡眠呼吸暂停（OSA）是一种影响3-7%的普通人群和40%的肥胖患者的疾病。一般来说，睡眠呼吸暂停的诊断和确定OSA治疗的疗效涉及在实验室睡眠期间过夜监测呼吸和其他身体功能。然而，由于加拿大睡眠实验室的能力有限，要做睡眠研究需要很长时间。下颌前移装置（MAD）设计用于治疗OSA。本项目的目的是设计、开发和评估一种具有成本效益的口内智能MAD，该MAD集成了多传感器平台和EEG电极。智能MAD将允许口内测量生理参数，如血氧饱和度，EEG信号，心率和呼吸率以及加速度计，以检测睡眠潜伏期，开始和持续时间。该平台将有可能在家中记录睡眠模式，并及时评估MAD治疗的有效性。目前市场上没有智能MAD。为患者提供这种设备应该有助于iMD Research在生产的前24个月内获得预计10%的魁北克MAD市场份额。由于MAD的生理监测功能，Metropole Dentaire将能够治疗更大比例的OSA人群，预计在最初生产的2年内将翻一番。加拿大的医疗服务提供者将能够定期记录患者的睡眠情况，并评估MAD治疗的有效性，而无需将患者送往睡眠实验室。因此，它将降低对睡眠实验室的大量需求，并降低加拿大的治疗成本。记录患者的睡眠数据将有助于推进加拿大的睡眠呼吸暂停研究和治疗。未来，多传感平台和EEG电极将嵌入其他口腔内可穿戴设备中，以在家中诊断睡眠呼吸暂停和其他健康状况。这将有助于更快地诊断睡眠呼吸暂停，减少未经治疗的睡眠呼吸暂停患者的数量，从而减少与未经治疗的睡眠呼吸暂停相关的经济损失。此外，这将减少加拿大医疗保健系统对健康状况诊断的等待时间。

Obstructive Sleep Apnea (OSA) is a condition that affects 3-7% of the general population and 40% of patients with obesity. Generally, diagnosis of sleep apnea and determining the efficacy OSA treatment involve overnight monitoring of breathing and other body functions during sleep at labs. However, due to the limited capacity of sleep labs in Canada there is a long waiting to do sleep studies. Mandibular Advancement Device (MAD) is designed to treat OSA. The aim of this project is to design, develop and evaluate a cost effective intraoral smart MAD integrating a multi sensor platform and EEG electrodes. The smart MAD will allow intraoral measurement of physiological parameters such as blood oxygen saturation, EEG signal, heart and breathing rate as well as accelerometry to detect sleep latency, onset and duration. The platform will have potential to document sleep patterns from home and evaluate the effectiveness of MAD treatment on time. There are currently no intelligent MADs on the market. Providing patients with such a device should help iMD Research acquire a projected 10% of Quebec MAD market share within the first 24 months of production. Due to the physiological monitoring feature of the MAD, Metropole Dentaire will be able to treat a much larger portion of the OSA population expected to double within 2 years of initial production. The healthcare providers in Canada will be able to document patient's sleep on a regular basis and evaluate the effectiveness of the MAD treatment without sending them to sleep labs. Thus, it will lower the heavy demand on sleep labs and lower the treatment cost in Canada. Documenting the sleep data on patients will help advance the sleep apnea research and treatment in Canada. In the future, the multi sensing platform and the EEG electrodes will be embedded in other intraoral wearable devices to diagnose sleep apnea and other health conditions from home. This will help diagnose sleep apnea faster and reduce the number of untreated sleep apnea patients, which, in turn, will reduce the economic loss related to untreated sleep apnea. Additionally, this will reduce the wait times in Canadian healthcare system for health condition diagnosis.